Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Moodys
Queensland Health
Novartis
Fish and Richardson
Chubb
Fuji
Julphar
UBS
Daiichi Sankyo

Generated: February 18, 2018

DrugPatentWatch Database Preview

Claims for Patent: 8,951,969

« Back to Dashboard

Summary for Patent: 8,951,969
Title:Compositions and methods for treating centrally mediated nausea and vomiting
Abstract: Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.
Inventor(s): Trento; Fabio (Como, IT), Cantoreggi; Sergio (Cagiallo, CH), Rossi; Giorgia (Como, IT), Cannella; Roberta (Varese, IT), Bonadeo; Daniele (Varese, IT)
Assignee: Helsinn Healthcare SA (Lugano/Pazzallo, CH)
Application Number:14/069,885
Patent Claims: 1. An oral pharmaceutical dosage form comprising about 0.56 mg of palonosetron hydrochloride and about 300 mg of netupitant as the free base.

2. An oral pharmaceutical dosage form in the form of a capsule comprising a hard outer shell, three tablets comprising about 100 mg of netupitant each, and one soft-gel capsule comprising about 0.56 mg of palonosetron hydrochloride, wherein the tablets and soft-gel capsule are housed within the hard outer shell.

3. The oral dosage form of claim 2, comprising 0.56 mg of palonosetron hydrochloride and 300 mg of netupitant as the free base.

4. The oral dosage form of claim 2, further comprising (3S)-3-[(3aS)-1-oxo-2,3,3a,4,5,6-hexahydro-1H-benzo[de]isoquinoline-2-yl]- -1-azoniabicyclo[2.2.2]octan-1-olate in an amount that does not exceed 3 wt. %.

5. The oral dosage form of claim 2, wherein said outer shell of said capsule has an oxygen permeability of less than 1.0.times.10.sup.-3 mlcm/(cm.sup.224 hr. atm).

6. The oral dosage form of claim 2, wherein each of said soft-gel capsules comprises an inner fill composition comprising from about 75 to about 98 wt. % of one or more lipophilic components.

7. A dosage form formulated for oral administration comprising a therapeutically effective amount of a) netupitant and b) palonosetron, wherein a single dose of the composition provides a median t.sub.max of netupitant that is about 0.5 hours shorter than is provided by a single dose of a composition having the same amount of netupitant alone.

8. A pharmaceutical composition formulated for oral administration comprising a therapeutically effective amount of a) netupitant and b) palonosetron, wherein a single dose of the composition provides a greater area under the curve (AUC) of netupitant than is provided by a single dose of a composition having the same amount of netupitant alone.

9. The pharmaceutical composition of claim 8, wherein the composition further provides a greater C.sub.max of netupitant than is provided by a single dose of a composition having the same amount of netupitant alone.

10. The pharmaceutical composition of claim 8, wherein the composition further provides a shorter t.sub.max of netupitant than is provided by a single dose of a composition having the same amount of netupitant alone.

11. The pharmaceutical composition of claim 10, wherein the median t.sub.max of netupitant is 0.5 hour shorter than is provided by a single dose of a composition having the same amount of netupitant alone.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Merck
Express Scripts
McKinsey
Chubb
Moodys
Mallinckrodt
Baxter
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot